Immunogen, Inc.

NASDAQ:IMGN  
4.61
+0.10 (+2.33%)
Products

Immunogen Announces Research Collaboration With Oxford Biotherapeutics To Develop Novel Antibody-Drug Conjugates

Published: 06/13/2022 10:43 GMT
Immunogen, Inc. (IMGN) - Immunogen Announces Research Collaboration With Oxford Biotherapeutics to Develop Novel Antibody-drug Conjugates.
Immunogen Inc - Companies to Research Antibody-drug Conjugates (adcs) to Address Cancers of High Unmet Need.
Immunogen Inc - Collaboration to Utilize Immunogen's Adc Linker-payload Technology Directed to Targets Identified by Obt.
Immunogen Inc - Each Company May Select a Number of Preclinical Programs for Internal Development.
Immunogen Inc - Obt to Receive an Upfront Payment; Each Company Eligible to Receive Milestone Payments Plus Tiered Royalties.